Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis

Journal of Medicinal Chemistry

Volumn 58, Issue 15, 2015, Pages 5942-5949

  Zhang, Yinan ^a,e   Zhao, Kevin Tianmeng ^a   Fox, Susan G ^a   Kim, Jinho ^b,c   Kirsch, Donald R ^d   Ferrante, Robert J ^b,c   Morimoto, Richard I ^a   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VA Pittsburgh Healthcare System   (United States)

^d Cambria Pharmaceuticals   (United States)

^e University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; MUTANT PROTEIN; N (3,5 DICHLOROBENZYL) N METHYL 1 (5 OXO 2,5 DIHYDRO 1H PYRAZOL 3 YL)METHANAMINIUM CHLORIDE; N (3,5 DICHLOROBENZYL) N METHYL 1 (5 OXO 2,5 DIHYDRO 1H PYRAZOL 3 YL)METHANAMINIUM DIBASIC PHOSPHATE; PYRAZOLONE DERIVATIVE; TERTIARY AMINE; UNCLASSIFIED DRUG; AMINE; INORGANIC SALT; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MICROSOME; CYTOTOXICITY ASSAY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; MALE; MOUSE; NONHUMAN; PLASMA HALF LIFE; PROTEIN AGGREGATION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; IN VITRO STUDY;

AMINES; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; MICE; PYRAZOLONES; SALTS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE;

EID: 84939135075     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00561     Document Type: Article

References (33)

1. Rowland, L. P.; Shneider, N. A. Amyotrophic lateral sclerosis N. Engl. J. Med. 2001, 344, 1688-1700 10.1056/NEJM200105313442207
2. Rothstein, J. D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis Ann. Neurol. 2009, 65 (S1) S3-S9 10.1002/ana.21543
3. Worms, P. M. The epidemiology of motor neuron diseases: a review of recent studies J. Neurol. Sci. 2001, 191, 3-9 10.1016/S0022-510X(01)00630-X
4. Mitsumoto, H.; Rabkin, J. G. Palliative care for patients with amyotrophic lateral sclerosis: "Prepare for the worst and hope for the best J. Am. Med. Assoc. 2007, 298, 207-216 10.1001/jama.298.2.207
5. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group N. Engl. J. Med. 1994, 330, 585-591 10.1056/NEJM199403033300901
6. Renton, A. E.; Chio, A.; Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics Nat. Neurosci. 2013, 17, 17-23 10.1038/nn.3584
7. Vucic, S.; Rothstein, J. D.; Kiernan, M. C. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies Trends Neurosci. 2014, 37, 433-442 10.1016/j.tins.2014.05.006
8. Özdinler, P. H.; Silverman, R. B. Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures ACS Med. Chem. Lett. 2014, 5, 1179-1181 10.1021/ml500404b
9. The ALS online genetics database. http://alsod.iop.kcl.ac.uk/.
10. Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis Nature 1993, 362, 59-62 10.1038/362059a0
11. Turner, B. J.; Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS Prog. Neurobiol. 2008, 85, 94-134 10.1016/j.pneurobio.2008.01.001
12. Nagai, M.; Re, D. B.; Nagata, T.; Chalazonitis, A.; Jessell, T. M.; Wichterle, H.; Przedborski, S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons Nat. Neurosci. 2007, 10, 615-622 10.1038/nn1876
13. Haidet-Phillips, A. M.; Hester, M. E.; Miranda, C. J.; Meyer, K.; Braun, L.; Frakes, A.; Song, S. W.; Likhite, S.; Murtha, M. J.; Foust, K. D.; Rao, M.; Eagle, A.; Kammesheidt, A.; Christensen, A.; Mendell, J. R.; Burghes, A. H. M.; Kaspar, B. K. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons Nat. Biotechnol. 2011, 29, 824-828 10.1038/nbt.1957
14. Perrin, S. Preclinical research: Make mouse studies work Nature 2014, 507, 423-425 10.1038/507423a
15. Ludolph, A. C.; Bendotti, C.; Blaugrund, E.; Chio, A.; Greensmith, L.; Loeffler, J.-P.; Mead, R.; Niessen, H. G.; Petri, S.; Pradat, P.-F.; Robberecht, W.; Ruegg, M.; Schwalenstöcker, B.; Stiller, D.; van den Berg, L.; Vieira, F.; von Horsten, S. Guidelines for preclinical animal research in ALS/MND: A consensus meeting Amyotrophic Lateral Scler. 2010, 11, 38-45 10.3109/17482960903545334
16. Matsumoto, G.; Stojanovic, A.; Holmber, C. I.; Kim, S.; Morimoto, R. I. Structure properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates J. Cell Biol. 2005, 171, 75-85 10.1083/jcb.200504050
17. Benmohamed, R.; Arvanites, A. C.; Kim, J.; Silverman, R. B.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R. Identification of compounds protective against G93A SOD1 toxicity for the treatment of amyotrophic lateral sclerosis Amyotrophic Lateral Scler. 2011, 12, 87-96 10.3109/17482968.2010.522586
18. Chen, T.; Benmohamed, R.; Arvanites, A. C.; Ranaivo, H. R.; Morimoto, R. I.; Ferrante, R. J.; Watterson, D. M.; Kirsch, D. R.; Silverman, R. B. Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis Bioorg. Med. Chem. 2011, 19, 613-622 10.1016/j.bmc.2010.10.052
19. Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D.; Silverman, R. B. ADME-guided design and synthesis of aryloxanylpyrazonlone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protective aggregation: Potential application for the treatment of amyotrophic lateral sclerosis J. Med. Chem. 2012, 55, 515-527 10.1021/jm2014277
20. Zhang, Y.; Benmohamed, R.; Huang, H.; Chen, T.; Voisine, C.; Morimoto, R. I.; Kirsch, D. R.; Silverman, R. B. Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis J. Med. Chem. 2013, 56, 2665-2675 10.1021/jm400079a
21. Trippier, P. C.; Zhao, K. T.; Fox, S. G.; Schiefer, I. T.; Benmohamed, R.; Moran, J.; Kirsch, D. R.; Morimoto, R. I.; Silverman, R. B. Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis ACS Chem. Neurosci. 2014, 5, 823-829 10.1021/cn500147v
22. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure, Design, and Methods; Academic Press: London, 2008; p 65.
23. Pardridge, W. M. CNS drug design based on principles of blood-brain barrier transport J. Neurochem. 1998, 70, 1781-1792 10.1046/j.1471-4159.1998.70051781.x
24. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583 10.1021/jm060642i
25. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584-2608 10.1021/jm501535r
26. Van de Waterbeemd, H.; Gifford, E. ADMET in silico modeling: towards prediction paradise? Nat. Rev. Drug Discovery 2003, 2, 192-204 10.1038/nrd1032
27. Lohmann, C.; Huwel, S.; Galla, H. J. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays J. Drug Targeting 2002, 10, 263-276 10.1080/10611860290031903
28. Alavijeh, M. S.; Chishty, M.; Qaiser, M. Z.; Palmer, A. M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery NeuroRx 2005, 2, 554-571 10.1602/neurorx.2.4.554
29. Zhang, Y.; Benmohamed, R.; Zhang, W.; Kim, J.; Edgerly, C. K.; Zhu, Y.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis ACS Med. Chem. Lett. 2012, 3, 584-587 10.1021/ml3000963
30. Kerns, E. H.; Di, L. Multivariate pharmaceutical profiling for drug discovery Curr. Top. Med. Chem. 2002, 2, 87-98 10.2174/1568026023394470
31. Robertson, J. S. Blood pressure maxima in humans J. Clin. Basic Cardiol. 2006, 9, 37-40
32. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; LaPerle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174 10.1124/dmd.104.001230
33. Xia, G.; Benmohamed, R.; Kim, J.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis J. Med. Chem. 2011, 54, 2409-2421 10.1021/jm101549k